

FIRST \$1.4M CONTRACT FOR ROVER LAUNCHES MICRO-X SECOND PRODUCT

World Health Organisation deal for Rover into Pacific Island Nations

Adelaide, Australia, 30th September 2020: Australian hi-tech company Micro-X Ltd (ASX:MX1) (**Micro-X** or the **Company**), a leader in cold cathode x-ray technology for health and security markets globally, is pleased to announce that today it has signed its first contract for sales of Micro-X's second product, the Rover.

Key Points

- **\$1.4M contract facilitated by World Health Organisation for Rover X-ray units**
- **Delivery to Governments of a number of Pacific island nations**
- **Extended sales strategy for Rover – where rugged and expanded mobility features are attractive**

Commercialisation of the Rover

Since FDA clearance on 20 July 2020, Micro-X has been focussing most of its sales efforts on securing Rover business with its target military customers in the Australian, US and UK armed forces. In addition, the Micro-X sales team has been exploring other deployable applications where the rugged and independent operational capabilities of the Rover offer practical customer benefits. This agreement for sales of Rover units totalling \$1.4 million has been enabled by the World Health Organisation and demonstrates the attractiveness of Rover's flexibility and extreme mobility across a broad range of operational scenarios. Deliveries, via an in-country agent, are destined for the Governments of a number of Pacific Island nations and are due to be made from Adelaide in the next 4 weeks.

This marks a first success for the Company's new direct marketing strategy for Rover which enables the Company to move up the value-chain compared to our earlier OEM business model.

Background on the Rover mobile X-ray

The need for a full-performance, digital, mobile medical x-ray imager, ruggedised and light enough to be used in deployed or temporary medical facilities was first identified to the Company by the Australian Army. The 'Rover' product was subsequently developed under a contract from the Australian Department of Defence which proved that Micro-X's technology could fulfil this operational requirement. The Rover's design incorporates the core elements of Micro-X's first bedside imaging product and has attracted acclaim for the focus on rugged construction, operator workflow features, manoeuvrability, long-life battery operation and other specialised features for robust mobility on uneven and temporary surfaces.

Micro-X's Managing Director, Peter Rowland, commented:

"Achieving this first deal for the Rover product less than 2 months after receiving FDA clearance is a significant step for Micro-X as we further grow revenue and become a commercially focused technology business. This contract also marks an important milestone in the growth of our internal sales capability as we embark on an aggressive sales strategy for the Rover product. We are delighted with the positive feedback received for Rover and we aim to sustain this revenue momentum throughout the financial year."

This ASX Announcement is authorised by the Board of Micro-X

– ENDS –

For personal use only

About Micro-X

Micro-X Limited (the **Company**) is an ASX listed hi-tech company developing and commercialising a range of innovative products for global health and security markets, based on proprietary cold cathode, carbon nanotube (CNT) emitter technology. The electronic control of emitters with this technology enables X-ray products with significant reduction in size, weight and power requirements, enabling greater mobility and ease of use in existing X-ray markets and a range of new and unique security and defence applications. Micro-X has two mobile digital medical X-ray systems being sold commercially for diagnostic healthcare applications and Micro-X medical products are now in operation in 14 countries around the world.

Micro-X has a portfolio of innovative products in development, including the MBI for imaging Improvised Explosive Devices in security, defence and counter-terrorism applications; a next-generation self-service X-Ray Airport Checkpoint Portal with an integrated body scanner; and a lightweight brain CT imager for early stroke diagnosis in ambulances. Micro-X has its core R&D, engineering and production capability in Adelaide, Australia with a fully in-sourced CNT tube manufacturing line and approximately 95% Australian locally manufactured content.

CONTACTS

Micro-X Limited	Investor Enquiries
<p>Peter Rowland Managing Director Tel: +61 8 7099 3966 E: admin@micro-x.com</p>	<p>David Allen / John Granger Hawkesbury Partners Tel: +61 2 9103 9494 E: dallen@hawkesburypartners.com jgranger@hawkesburypartners.com</p>

For personal use only